“Neurodegenerative Diseases Market to 2018
- New product entries in
both niche and broader Parkinson’s disease treatment will boost marketdespite patent cliff”. A highly dynamic market scenario is expected in
Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for
Alzheimer’s disease has not seen any recent major breakthroughs, and is
expected to experience a decline due to the patent expiry of several major
products. The market for Parkinson’s disease, on the other hand, is
expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that itwill soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.